Insider Selling: Illumina (NASDAQ:ILMN) Director Sells $29,546,094.69 in Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 131,019 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $225.51, for a total transaction of $29,546,094.69. Following the completion of the transaction, the director owned 1,278,832 shares of the company’s stock, valued at approximately $288,389,404.32. The trade was a 9.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Illumina Stock Performance

Illumina stock opened at $215.59 on Friday. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $231.81. The firm’s 50 day simple moving average is $194.05 and its 200-day simple moving average is $155.60. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company has a market cap of $32.55 billion, a P/E ratio of 40.22, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ILMN shares. Guggenheim raised their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. upped their price target on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. Canaccord Genuity Group raised their price objective on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Finally, Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $188.40.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
• Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
• Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
• Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
• Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
• Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Institutional Investors Weigh In On Illumina

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. HighPoint Advisor Group LLC grew its holdings in shares of Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after purchasing an additional 80 shares during the last quarter. Elevation Wealth Partners LLC lifted its holdings in Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares during the last quarter. Meeder Advisory Services Inc. boosted its position in Illumina by 3.1% in the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after buying an additional 85 shares in the last quarter. Toronto Dominion Bank boosted its position in Illumina by 0.3% in the fourth quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after buying an additional 92 shares in the last quarter. Finally, Panagora Asset Management Inc. grew its stake in Illumina by 3.9% during the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after buying an additional 96 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.